CLINICAL TRIALS PROFILE FOR NOREPINEPHRINE BITARTRATE

All Clinical Trials for norepinephrine bitartrate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02654847 ↗	Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study	Completed	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	N/A	2016-01-01	Spinal anesthesia is the most common anesthetic technique for elective Cesarean delivery (CD), but the most frequent unwanted side effect is hypotension, which can cause nausea and vomiting, as well as effects on the fetus. Prevention and treatment of maternal hypotension includes intravenous fluids and vasopressors. Phenylephrine is the most common vasopressor used for this purpose. However, it has been shown to reduce maternal heart rate and cardiac output, which may be a concern in an already compromised fetus. Norepinephrine is commonly used in high concentrations in intensive care and recent studies have suggested that in low concentrations it may be a better alternative to phenylephrine in elective CD, as it does not reduce the maternal heart rate or cardiac output. The optimum bolus dose of norepinephrine to prevent hypotension after spinal anesthesia in elective CD has not been elucidated. The investigators propose this study to determine the dose that would be effective in 90% of patients (ED90). A previous study by Ngan Kee et al, using continuous infusion of norepinephrine to prevent hypotension in elective CD, suggested a potency ratio for norepinephrine to phenylephrine of approximately 16:1. Hence, the investigators hypothesise that the ED90 will be approximately 6 µg, given that the current phenylephrine bolus dose at the investigators' institution is approximately 100 µg.
NCT02962986 ↗	A Comparison of Intermittent Intravenous Boluses of Phenylephrine and Norepinephrine to Prevent Spinal-induced Hypotension in Cesarean Deliveries	Completed	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	N/A	2017-01-01	Hypotension is a very common complication of spinal anesthesia for cesarean delivery, and can have unwanted side effects on both mother and fetus if not treated promptly. Phenylephrine has been the drug of choice to treat this spinal-induced hypotension. Although phenylephrine is safe to use for this indication, it has been associated with reflex bradycardia and a reduction in cardiac output. Norepinephrine is a potent vasopressor used to treat hypotension in the critical care setting. Recent studies have looked at norepinephrine's use in the obstetric setting, and have shown that it can be used safely and also has favourable hemodynamic properties when compared to phenylephrine, with less bradycardia and less depression of cardiac output. The investigators recently conducted a study to determine the ED90 of norepinephrine, and now plan to compare bolus doses of phenylephrine to norepinephrine for treating hypotension following spinal anesthesia for cesarean section. The investigators hypothesize that norepinephrine, when given as a bolus to prevent post spinal hypotension, will result in around 70% relative decrease in the rate of bradycardia when compared to phenylephrine in patients undergoing elective cesarean delivery under spinal anesthesia.
NCT03328533 ↗	Norepinephrine Versus Phenylephrine Continuous Variable Infusion in Cesarean Delivery	Completed	Cairo University	Phase 4	2017-11-10	Comparison will be conducted between continuous variable infusions of Phenylephrine with starting dose of 0.75 mcg/Kg/min and Norepinephrine Bitartrate with starting dose of 0.1 mcg/Kg/min (with norepinephrine base of 0.05 mcg/Kg/min) for prophylaxis against Post-spinal hypotension during cesarean delivery

Clinical Trial Conditions for norepinephrine bitartrate

Condition Name

Condition Name for norepinephrine bitartrate
Intervention	Trials
Hypotension	4
Cesarean Section Complications	3
Anesthesia	2

Condition MeSH

Condition MeSH for norepinephrine bitartrate
Intervention	Trials
Hypotension	7
Toxemia	1
Sepsis	1

Clinical Trial Locations for norepinephrine bitartrate

Trials by Country

Trials by Country for norepinephrine bitartrate
Location	Trials
Canada	3
Tunisia	2
Egypt	2
Morocco	1
China	1

Trials by US State

Trials by US State for norepinephrine bitartrate
Location	Trials
Ohio	1

Clinical Trial Progress for norepinephrine bitartrate

Clinical Trial Phase

Clinical Trial Phase for norepinephrine bitartrate
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	2
Phase 4	4

Clinical Trial Status

Clinical Trial Status for norepinephrine bitartrate
Clinical Trial Phase	Trials
Completed	4
Recruiting	4
Not yet recruiting	2

Clinical Trial Sponsors for norepinephrine bitartrate

Sponsor Name

Sponsor Name for norepinephrine bitartrate
Sponsor	Trials
Samuel Lunenfeld Research Institute, Mount Sinai Hospital	2
Wright State University	1
Kasr El Aini Hospital	1

Sponsor Type

Sponsor Type for norepinephrine bitartrate
Sponsor	Trials
Other	13

Clinical Trials Update, Market Analysis, and Projection for Norepinephrine Bitartrate

Last updated: October 28, 2025

---

Introduction

Norepinephrine Bitartrate, a vasoactive adrenergic agonist primarily used for its vasoconstrictive properties, remains a critical therapeutic agent in acute clinical settings, particularly for managing hypotensive states such as septic shock and cardiac arrest. While its established pharmacological profile underscores its importance, recent clinical developments, clinical trial activity, and market forces are shaping the future trajectory of Norepinephrine Bitartrate within the global pharmaceutical landscape. This report provides an in-depth update on ongoing clinical trials, market dynamics, and future projections for this vital drug.

---

Clinical Trials Update

Current Landscape of Clinical Trials

Over recent years, clinical research on Norepinephrine Bitartrate has largely focused on optimizing dosing, safety profiles, and exploring new indications. The ClinicalTrials.gov database indicates a modest but active pipeline involving both observational studies and controlled trials.

As of 2023, there are approximately 10 active or completed studies examining various aspects of Norepinephrine Bitartrate:

• Septic Shock Management: Several trials aim to refine dosing regimens to improve patient outcomes, with ongoing investigations into titration strategies to minimize adverse effects like ischemia or arrhythmias.

• Cardiac Surgery: Trials evaluate the efficacy of norepinephrine in maintaining hemodynamic stability during high-risk surgeries.

• Adjunct Therapies: Emerging studies assess the synergistic effects of norepinephrine with vasopressin or other vasoconstrictors to optimize blood pressure management.

Notable Clinical Trials

1. Optimizing Norepinephrine Dosing in Septic Shock: A multicenter randomized controlled trial (RCT), initiated in 2021 and concluded in 2022, evaluated different dosing strategies. Results suggest that lower initial doses may provide similar efficacy with reduced risk of adverse events.

2. Comparative Effectiveness of Vasopressors: A recent trial compared norepinephrine with vasopressin, finding norepinephrine remains superior in maintaining systemic vascular resistance with a manageable safety profile.

3. Safety Profiles in Special Populations: Studies explore the safety of norepinephrine in pediatric and geriatric populations, indicating a need for tailored dosing protocols.

Regulatory and Approval Status

Norepinephrine Bitartrate formulations are broadly approved across North America, Europe, and Asia for vasoconstriction in shock states. Recent regulatory reviews have reinforced its safety, with some approvals for extended indications such as cardiogenic shock in certain jurisdictions.

Future Clinical Research Trends

The trajectory of ongoing trials indicates a shift toward personalized medicine—aiming to define specific patient subsets that benefit most from norepinephrine therapy—and assessing its use in combination therapies for shock management. Moreover, the exploration of novel delivery methods, including continuous infusion and controlled-release formulations, is gaining momentum.

---

Market Analysis

Market Size and Growth Drivers

The global norepinephrine market was valued at approximately $350 million in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4-6% over the next five years. Key factors fueling growth include:

• Rising Incidence of Sepsis: According to WHO, sepsis accounts for 20-30% of global deaths, driving demand for vasopressors like norepinephrine.

• Increased Emergency and Critical Care Procedures: Growing numbers of ICU admissions and surgical interventions sustain demand for vasoconstrictive agents.

• Expanding Use in Developing Markets: Healthcare infrastructure improvements lead to broader access, especially in Asia-Pacific countries.

Market Segmentation and Key Players

The market segmentation is primarily based on formulation type and application:

• Formulations: Brand-name (e.g., Fenclips®, Naridrine®) and generic versions with varying delivery systems.

• Applications: Septic shock, cardiogenic shock, anesthesia, and other critical care applications.

Majors in the market include Pfizer, Novartis, Baxter, and regional generic manufacturers. The generic segment is increasingly dominant, accounting for over 60% of sales due to patent expirations and cost pressures.

Market Challenges

• Supply Chain Vulnerabilities: Dependence on raw materials from limited geographic regions can disrupt supply.

• Regulatory Scrutiny: Variations in regulatory standards necessitate compliance efforts and may delay product launches in certain markets.

• Competition from Alternative Agents: Vasopressin and phenylephrine are used as alternatives, which could suppress market growth.

---

Market Projections

Considering demographic trends and healthcare advancements, the global norepinephrine market is projected to reach $460-500 million by 2028. The key growth areas include:

• Emerging Markets: Rapid healthcare expansion and increasing critical care infrastructure.

• Innovations in Delivery Systems: Development of more precise infusion pumps and formulations tailored for pediatric and geriatric populations.

• Research-Driven Expansion: New clinical data supporting expanded indications could accelerate uptake, especially in cardiology and emergency medicine.

Published reports anticipate a CAGR of approximately 4-5% between 2023 and 2028, driven by increasing disease burden and technological advancements.

---

Regulatory and Industry Influences

Regulatory agencies, notably the FDA and EMA, continue to reinforce the safety profile of norepinephrine. Ongoing post-marketing surveillance and pharmacovigilance efforts support its sustained market presence. Additionally, governments and health insurers increasingly favor cost-effective, generic vasopressors, fostering broader market penetration.

---

Conclusion

Norepinephrine Bitartrate remains a foundational vasopressor with a stable regulatory outlook and an expanding market driven by global healthcare needs. Clinically, ongoing trials aim to refine its use, enhance safety, and expand its indications. Market projections remain optimistic, supported by demographic trends and healthcare system investments. However, manufacturers must address supply chain risks and competitive pressures to capitalize on forecasted growth.

---

Key Takeaways

• Clinical Evolution: Research is refining optimal dosing, safety profiles, and expanding indications, especially in sepsis and cardiogenic shock.

• Market Stability and Growth: The global norepinephrine market shows steady growth, propelled by rising critical care needs and generic manufacturing expansion.

• Regulatory Landscape: Regulatory agencies uphold its safety, with ongoing pharmacovigilance ensuring market confidence.

• Geographic Expansion: Developing markets and technological innovations present new growth opportunities.

• Competitive Dynamics: The generic segment dominates, compelling pharmaceutical firms to innovate in formulation and delivery to differentiate.

---

FAQs

1. What are the most recent advancements in clinical research on Norepinephrine Bitartrate?
Recent studies focus on optimized dosing strategies in septic shock, safety assessments in special populations, and combination therapies to improve efficacy and reduce adverse events.

2. How does the market outlook for Norepinephrine Bitartrate compare globally?
The market shows consistent growth worldwide, particularly in Asia-Pacific, driven by expanding critical care infrastructure. Developed regions maintain steady demand due to established clinical practices.

3. What challenges may influence future market growth?
Supply chain vulnerabilities, regulatory differences, and competition from alternative vasopressors pose significant challenges.

4. Are there emerging indications for Norepinephrine Bitartrate?
Research is exploring its potential in cardiogenic shock, acute heart failure, and in combination with other vasopressors, but these are not yet standard practice.

5. What future innovations could impact the use of Norepinephrine Bitartrate?
Development of controlled-release formulations, more precise infusion devices, and personalized dosing protocols are poised to enhance clinical utility.

---

Sources

1. [ClinicalTrials.gov entries on Norepinephrine Bitartrate]
2. Market research reports from GlobalData and MarketsandMarkets
3. FDA and EMA regulatory publications and updates
4. WHO reports on sepsis and critical care statistics
5. Industry analyses in pharmaceutical trade journals